Aug. 17, 2016
Shanghai-based Ark Biosciences announced the beginning of its global Phase II trial of AK0529, a novel treatment for respiratory syncytial virus (RSV) on Aug. 17, 2016. RSV is a common infection among infants, and although usually not serious, it is the leading cause of hospitalization in infants under the age of one. The orally administered drug specifically inhibits RSV replication by blocking viral entry and syncytium formation, the latter a unique viral transmission and cell-cell fusion phenomenon which gives the virus its name. Ark Biosciences in-licensed the global rights to ARK0529 from Roche two years ago.